Navigation Links
Successful Phase I/II Clinical Trial Results From Cancer Patients Treated With Anti-Cancer Drug From Axelar AB
Date:5/6/2009

STOCKHOLM, May 6 /PRNewswire/ -- Axelar AB today announced successful completion of the single-day oral dosing part of its ongoing phase I/II clinical trial on cancer patients with its new anti-cancer drug AXL1717,an insulin-like growth factor-1 (IGF-1) receptor inhibitor which has no effects on the closely related insulin receptor. The study is conducted in Sweden on patients having terminal cancer disease. The results showed that a single-day dosing of AXL1717 could be successfully escalated with excellent tolerability. No dose-limiting toxicity was reported. The next part of the trial has now been approved, including a seven-day dosing BID regimen instead of single-day BID treatments. The first patients have already been treated with AXL1717 for seven days.

The ongoing phase I/II clinical trial is primarily designed to assess the safety, tolerability, and pharmacokinetics of the drug. As a secondary objective, anti-cancer effects are documented whenever possible.

"We are very pleased that high doses of AXL1717 could be administered to patients without significant side effects during the single-day treatments.", says Johan Harmenberg, CEO of Axelar AB. "Targeting cancer cells with AXL1717 instead of conventional cytotoxic chemotherapy may be a new and well-tolerated treatment alternative for cancer patients in the future."

The IGF-1 receptor is a promising target for the treatment of cancer, since the receptor is crucial for the survival and growth of malignant cells. In contrast, the IGF-1 receptor is not absolutely necessary for growth of normal cells.

AXL1717 is a small-molecule IGF-1 receptor inhibitor with no effect on the important and almost identical insulin receptor. Pre-clinical data show an extraordinary anti-tumor efficacy in animal models, including apparent complete tumor regression, for a wide range of human cancers such as breast cancer, prostate cancer, malig
'/>"/>

SOURCE Karolinska Development AB
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Symphony Medical Announces First Patient Successfully Treated With Novel Congestive Heart Failure Therapy
2. Zenobia Therapeutics Successfully Completes Initial Phase of Its Service Agreement With Syntonix Pharmaceuticals
3. VeraSun Energy Selects Valero as Successful Bidder for Seven Facilities
4. Bavarian Nordic Has Essentially Agreed a Pathway for the Licensure of IMVAMUNE(R) With the FDA After Successful End of Phase II Meeting
5. EnWave Successfully Commercializes nutraREV(TM) Food Dehydration Technology
6. Endo Pharmaceuticals Successfully Completes Tender Offer for Shares of Indevus Pharmaceuticals and Announces Subsequent Offering Period
7. DiFUSION Technologies Completes Successful Testing of Antimicrobial Spinal Implant
8. WaferGens SmartChip(TM) System Performance Successfully Demonstrated in Initial Phase of Alpha Testing Program
9. GlaxoSmithKline Successfully Completes Tender Offer for Shares of Genelabs Technologies, Inc.
10. Star Scientific Announces Successful Completion of Product Satisfaction Study - Results Show Potential for Development and Manufacturing of New Pharmaceutical Product for Smoking and Smokeless Tobacco Cessation
11. Strativa Pharmaceuticals Announces Successful Completion of Bioequivalence Studies for Ondansetron Thin Film
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... , Jan. 22, 2015   GenoSpace , a precision medicine ... to enable the broad use of genomic, imaging and other ... appointment of Michelle Munson , CEO of Aspera, an ... Logo - http://photos.prnewswire.com/prnh/20150122/170713 "We ...
(Date:12/24/2014)... YORK , Dec. 24, 2014 PlasmaTech Biopharmaceuticals, Inc. ... critical areas, announced the closing of an underwritten public offering ... up to an aggregate 3,500,000 shares of common stock, at ... warrant.  The warrants have a per share exercise price of ...
(Date:12/24/2014)... 2014 GMO corn cases filed across the ... the process of being consolidated in a Kansas federal court ... AG MIR 162 Corn Litigation, MDL No. 2591 in the ... of the Syngenta GMO corn multidistrict litigation (MDL) has been ...
(Date:12/24/2014)... Island, New York (PRWEB) December 23, 2014 ... and the Long Island Affiliate of ITRA Global, the national ... slow but steady recovery. This is evidenced by the ... the strong stock market. Low energy costs have held ...
Breaking Biology Technology:GenoSpace Expands Board with Appointment of Michelle Munson 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 3
... -- I continue to be encouraged by the numerous ... Midwest. Here are just a few: , ,& bull; The ... 2006. , ,& bull; The continued acquisition of Midwest ... recognize the value of Midwest products and technology, the flip ...
... in Memphis, Tenn., will install a wireless distribution ... organization's corporate office under a $6 million agreement with ... distribution system will provide wireless coverage throughout Baptist's six ... system, which will be installed in the next 12 ...
... a biophysical chemist at the University of Wisconsin-Madison, has ... the Biophysical Society, a 7,000-member U.S. organization that represents ... and biochemistry, Record hopes that the new honor will ... funding for his research. , ,A UW-Madison faculty member ...
Cached Biology Technology:Midwest biotech on a roll 2Midwest biotech on a roll 3Midwest biotech on a roll 4
(Date:1/22/2015)... 22, 2015 Research and Markets ( ... "Global Wearable Technologies Market and Applications, Opportunities, ... and Forecast 2014-2020" report to their offering. ... devices that can be worn on the user,s ...
(Date:12/24/2014)... , Dec. 23, 2014  Since its launch in December 2014, ... to eliminate the pain of trying to remember their usernames ... biometrics fused to their smartphones. To assist people who have ... the company that created 1U and focuses on redefining identity, ...
(Date:12/22/2014)... , Dec. 22, 2014  The 2014 Holiday Season ... as Acuity Market Intelligence reports that the long anticipated ... forecasts that intensifying demand for smart phones, tablets, and ... global market of 2.5 billion users with nearly 4.8 ...
Breaking Biology News(10 mins):Global Wearable Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, Size, Growth, Share, Overview, Trends and Forecast 2014-2020 21U Offers Best Solution to the Username / Password Dilemma: For FREE! 21U Offers Best Solution to the Username / Password Dilemma: For FREE! 3First Season of Holiday Shopping with Mobile Biometric Payments Wraps Up With a Present for Biometrics Industry: A Rosy Forecast for More Than 2 Billion Users of 4.8 Billion Mobile Biometric Devices by 2020 2
... as well known for keeping us healthy as it is ... a new research report appearing in the March 2010 print ... scientists explain how they developed a genetically modified strain of ... scum, scientifically known as microcystin-LR (MC-LR), which makes water unsafe ...
... silkworm moths, butterflies and spiders, caddisfly larvae spin silk, but ... of Utah researchers have discovered why the fly,s silk is ... as an adhesive tape during surgery. "Silk from caddisfly ... may be useful some day as a medical bioadhesive ...
... of business for any fledgling plant embryo is to determine which ... researchers at the Salk Institute expose the turf wars between two ... polar axis with a root on one end and a shoot ... important decision for a plant, setting up the root/shoot axis, occurs ...
Cached Biology News:Glue, fly, glue 2Glue, fly, glue 3Glue, fly, glue 4Glue, fly, glue 5Root or shoot 2Root or shoot 3
... Engine Dyad instrument is the most advanced ... MJ's world-class thermal performance, the Dyad also ... well as point-and-click navigation via touch pad ... be easily and economically expanded to a ...
...
...
... instrument is the most advanced thermal cycler ... thermal performance, the Dyad also boasts graphical ... point-and-click navigation via touch pad or mouse. ... and economically expanded to a four-bay system ...
Biology Products: